ABOUT US
Our team combines technical expertise and clinical experience to build tools that are scientifically robust and truly useful for patients and healthcare professionals.
It includes:
- AI researchers
- Computer Engineers
- Dermatologists and clinical advisors
ARTICLES
OUR PARTNERS
DermIA collaborates with institutions committed to excellence in research, innovation and technology transfer.
University of Insubria
DermIA has been officially recognised as a spin-off of the University of Insubria.
The project originates from academic research dedicated to advanced dermatological image analysis and was developed within the University’s Contamination Lab, where it matured and progressed until achieving spin-off accreditation in 2025.
This recognition strengthens our collaboration with the University, which will provide resources and expertise to support the upcoming phases of development and technology transfer.
ComoNExT – Innovation Hub
DermIA was selected as a winner of the ComoNExT Incubator Program, a competitive initiative designed to accelerate the development of high-potential startups.
Through ComoNExT, we benefit from a qualified innovation ecosystem, business development support and strategic connections with industrial and technological partners.
BECOME A PARTNER
DermIA actively seeks collaborations with organisations aiming to advance digital health and medical innovation.
We offer several models of partnership:
- Joint research and development with universities and clinical centres
- Technology integration into medical software platforms or physical devices
- Clinical validation studies to assess performance in real-world environments
- Co-development of new AI modules tailored to specific imaging or diagnostic challenges
- Pilot programs for healthcare institutions interested in adopting AI-supported dermatology workflows
- Industrial collaborations for extending our technology into new application domains
Our goal is to establish long-term partnerships that combine scientific excellence, technological innovation and measurable clinical impact.
